SCHEMBL483975

SCHEMBL483975

CCOC(CNc1ccc(N2CCOCC2)c(F)c1)OCC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
HTT P42858 2/20 0.45
GAA P10253 6/20 0.44
ALOX15 P16050 2/20 0.44
MAPK1 P28482 1/20 0.44
RAB9A P51151 2/20 0.44
LDHA P00338 1/20 0.44
LDHB P07195 1/20 0.44
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 2/20 0.42
MAPT P10636 1/20 0.42
HSD17B10 Q99714 1/20 0.42
MTOR P42345 2/20 0.41
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL484019 0.88 GAA (0.48) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL16189751 0.83 NPC1 (0.50) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL5417803 0.78 HTT (0.49) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL2867969 0.78 HTT (0.49) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL15618724 0.78 HTT (0.49) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL23030168 0.78 HTT (0.49) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL12126890 0.78 HTT (0.49) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL15623485 0.78 HTT (0.49) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL28998621 0.77 HTT (0.48) NPC1L3MBTL1HTTGAAALOX15
SCHEMBL27627548 0.77 HTT (0.52) NPC1L3MBTL1HTTGAAALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US claimed
EP-2072505-B1 A process for the preparation of oxazolidinone derivatives DIPHARMA FRANCIS SRL (IT) 2012-02-01 EP disclosed
EP-2072505-A2 A process for the preparation of oxazolidinone derivatives Dipharma Francis S.r.l. (IT) 2009-06-24 EP disclosed
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives DIPHARMA FRANCIS S.R.I. (IT) 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156806-A1 Process for the Preparation of Oxazolidinone Derivatives OXA1L, AAAS, MLYCD NPC1 4601/4885L3MBTL1 3732/4885HTT 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.